{'fraction_non_alphanumeric': 0.02459954233409611, 'fraction_numerical': 0.03546910755148741, 'mean_word_length': 5.031034482758621, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The charitable trust as a model for genomic biobanks.

the authors reply: We are gratified to learn that there was only a small, statistically nonsignificant excess of asthma episodes among recipients of the 7-valent conjugate pneumococcal vaccine in the northern California study. 1 Differences in study design, follow-up, and detection of cases make direct comparisons of rates difficult to interpret. The administration of meningococcal conjugate in controls and the continued inclusion in the control group of the 23 percent of controls who received pneumococcal vaccine after the completion of the trial may have reduced the strength of the association between vaccination and asthma in that study. On the assumption of a follow-up time per group of 107,000 person-years in the California study, 1 the intentionto-treat rates of asthma episodes in that study were 760 per 100,000 person-years among vaccinees and 707 per 100,000 person-years among controls (an excess of 53 episodes per 100,000 person-years). In Soweto, South Africa, there were 128 episodes per 100,000 person-years in vaccinees and 71 per 100,000 in controls (an excess of 57 episodes per 100,000 person-years). The higher rates in California may be due to increased identification of outpatient diagnoses of asthma (the Soweto data include only patients in whom asthma was diagnosed at the hospital) and higher rates of asthma among older children included in the California follow-up study. Attack rates of asthma continue to be monitored in our trial, and these data suggest that they should continue to be monitored in post-marketing surveillance and in ongoing trials of pneumococcal conjugate vaccine in the Czech and Slovak Republics, the Gambia, and the Philippines.